A Modern Curriculum for Training Scientists in Model‐Informed Drug Development: Progress Report on FDA Grant to Train Regulatory Scientists

Author:

Barrett Jeffrey S.1ORCID,Romero Klaus1,Rayner Craig2,Gastonguay Marc3ORCID,Pillai Goonaseelan (Colin)45ORCID,Tannenbaum Stacey6,Kern Steven7ORCID,Selich Mark1,Francisco Dave1

Affiliation:

1. Critical Path Institute Tucson Arizona USA

2. Certara Princeton New Jersey USA

3. Metrum Research Group Tariffville Connecticut USA

4. Division of Clinical Pharmacology University of Cape Town Cape Town South Africa

5. CP+ Associates GmbH Basel Switzerland

6. Astellas Pharma Northbrook Illinois USA

7. Bill & Melinda Gates Foundation Seattle Washington USA

Abstract

Under US Food and Drug Administration (FDA) grant (2U18FD005320‐06), the Critical Path Institute (C‐Path) and experienced private sector partners collaborated with global health organizations to create didactic video materials in an e‐learning format on model‐informed drug development (MIDD) topics relevant to a non‐modeling audience. Several multinational pharmaceutical companies contributed case studies illustrating the application of the MIDD approach in practice. Training videos were created and divided into several modules: introducing the MIDD landscape for drug development and regulatory science, a review of various model types used for MIDD, discussions of how models inform drug development and regulatory decisions, future goals of MIDD, and discussions on the interconnectedness of models used for MIDD. Examples and vignettes from stakeholders and thought leaders were included. These educational materials fill a gap between academic and “on the job training” for regulators, academic, and industry scientists, delivering insights and value for those performing modeling and non‐modelers reviewing the output of modeling and simulation work. A total of 13 hours of video content is currently available. A small panel of FDA reviewers is currently beta‐testing the learning management system (LMS). Future efforts for this MIDD training initiative will include expansion of the content via an expanded and diverse faculty, 1:1 online mentorship sessions, and eventually broader access to this resource consistent with an open science approach and curriculum. The MIDD training LMS can accommodate a diverse learning ecosystem; further development may also accommodate different audiences in the future.

Publisher

Wiley

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Reflections on Model‐Informed Drug Development;Clinical Pharmacology & Therapeutics;2024-07-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3